These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

424 related articles for article (PubMed ID: 32269728)

  • 21. A Novel Orally Active Inverse Agonist of Estrogen-related Receptor Gamma (ERRγ), DN200434, A Booster of NIS in Anaplastic Thyroid Cancer.
    Singh TD; Song J; Kim J; Chin J; Ji HD; Lee JE; Lee SB; Yoon H; Yu JH; Kim SK; Yoon GS; Hwang H; Lee HW; Oh JM; Lee SW; Lee J; Choi HS; Na SY; Choi WI; Park YJ; Song YS; Kim YA; Lee IK; Cho SJ; Jeon YH
    Clin Cancer Res; 2019 Aug; 25(16):5069-5081. PubMed ID: 31010838
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Immunotherapy a New Hope for Cancer Treatment: A Review.
    Nouri Rouzbahani F; Shirkhoda M; Memari F; Dana H; Mahmoodi Chalbatani G; Mahmoodzadeh H; Samarghandi N; Gharagozlou E; Mohammadi Hadloo MH; Maleki AR; Sadeghian E; Nia E; Nia N; Hadjilooei F; Rezaeian O; Meghdadi S; Miri S; Jafari F; Rayzan E; Marmari V
    Pak J Biol Sci; 2018; 21(3):135-150. PubMed ID: 30187723
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Genetic alterations in anaplastic thyroid carcinoma and targeted therapies.
    Li Z; Zhang Y; Wang R; Zou K; Zou L
    Exp Ther Med; 2019 Oct; 18(4):2369-2377. PubMed ID: 31555347
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Salvage Lenvatinib Therapy in Metastatic Anaplastic Thyroid Cancer.
    Iñiguez-Ariza NM; Ryder MM; Hilger CR; Bible KC
    Thyroid; 2017 Jul; 27(7):923-927. PubMed ID: 28471306
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Personalized therapy in patients with anaplastic thyroid cancer: targeting genetic and epigenetic alterations.
    Smith N; Nucera C
    J Clin Endocrinol Metab; 2015 Jan; 100(1):35-42. PubMed ID: 25347569
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Anaplastic and poorly differentiated thyroid carcinoma: therapeutic strategies and treatment outcome of 52 consecutive patients.
    Siironen P; Hagström J; Mäenpää HO; Louhimo J; Heikkilä A; Heiskanen I; Arola J; Haglund C
    Oncology; 2010; 79(5-6):400-8. PubMed ID: 21455012
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cancer immunotherapy: the beginning of the end of cancer?
    Farkona S; Diamandis EP; Blasutig IM
    BMC Med; 2016 May; 14():73. PubMed ID: 27151159
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Precision Medicine-Enabled Cancer Immunotherapy.
    Lee JK; Priceman SJ
    Cancer Treat Res; 2019; 178():189-205. PubMed ID: 31209846
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Recent progress of genome study for anaplastic thyroid cancer.
    Lee J; Hwang JA; Lee EK
    Genomics Inform; 2013 Jun; 11(2):68-75. PubMed ID: 23843772
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Reintroducing the Sodium-Iodide Symporter to Anaplastic Thyroid Carcinoma.
    Schmohl KA; Dolp P; Schug C; Knoop K; Klutz K; Schwenk N; Bartenstein P; Nelson PJ; Ogris M; Wagner E; Spitzweg C
    Thyroid; 2017 Dec; 27(12):1534-1543. PubMed ID: 29032724
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Exceptional Response with Immunotherapy in a Patient with Anaplastic Thyroid Cancer.
    Kollipara R; Schneider B; Radovich M; Babu S; Kiel PJ
    Oncologist; 2017 Oct; 22(10):1149-1151. PubMed ID: 28778959
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Inverse Agonist of Estrogen-Related Receptor γ Enhances Sodium Iodide Symporter Function Through Mitogen-Activated Protein Kinase Signaling in Anaplastic Thyroid Cancer Cells.
    Singh TD; Jeong SY; Lee SW; Ha JH; Lee IK; Kim SH; Kim J; Cho SJ; Ahn BC; Lee J; Jeon YH
    J Nucl Med; 2015 Nov; 56(11):1690-6. PubMed ID: 26338896
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Anaplastic thyroid cancer.
    O'Neill JP; Shaha AR
    Oral Oncol; 2013 Jul; 49(7):702-6. PubMed ID: 23583302
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Evolving molecularly targeted therapies for advanced-stage thyroid cancers.
    Bible KC; Ryder M
    Nat Rev Clin Oncol; 2016 Jul; 13(7):403-16. PubMed ID: 26925962
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Immune Checkpoint Blockade in Breast Cancer Therapy.
    Bu X; Yao Y; Li X
    Adv Exp Med Biol; 2017; 1026():383-402. PubMed ID: 29282694
    [TBL] [Abstract][Full Text] [Related]  

  • 36. New targeted therapies for anaplastic thyroid cancer.
    Antonelli A; Fallahi P; Ulisse S; Ferrari SM; Minuto M; Saraceno G; Santini F; Mazzi V; D'Armiento M; Miccoli P
    Anticancer Agents Med Chem; 2012 Jan; 12(1):87-93. PubMed ID: 22043992
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A Systematic Review of Phase II Targeted Therapy Clinical Trials in Anaplastic Thyroid Cancer.
    Ljubas J; Ovesen T; Rusan M
    Cancers (Basel); 2019 Jul; 11(7):. PubMed ID: 31277524
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Immunotherapy: A New (and Old) Approach to Treatment of Soft Tissue and Bone Sarcomas.
    Nathenson MJ; Conley AP; Sausville E
    Oncologist; 2018 Jan; 23(1):71-83. PubMed ID: 28935774
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Current and Future Applications of Novel Immunotherapies in Urological Oncology: A Critical Review of the Literature.
    Özdemir BC; Siefker-Radtke AO; Campbell MT; Subudhi SK
    Eur Urol Focus; 2018 Apr; 4(3):442-454. PubMed ID: 29056275
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Novel therapeutic strategies in human malignancy: combining immunotherapy and oncolytic virotherapy.
    Sampath P; Thorne SH
    Oncolytic Virother; 2015; 4():75-82. PubMed ID: 27512672
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.